|
1
|
Bachet JP and Emile JF: Diagnostic
criteria, specific mutations and genetic predisposition in
gastrointestinal stromal tumors. Appl Clin Genet. 3:85–101.
2010.PubMed/NCBI
|
|
2
|
Blay JY and Reichardt P: Advanced
gastrointestinal stomal tumour in Europe: a review of updated
treatment recommendations. Expert Rev Anticancer Ther. 9:1–8.
2009.PubMed/NCBI
|
|
3
|
Gupta P, Tewari M and Shukla HS:
Gastrointestinal stromal tumor. Surg Oncol. 17:129–138. 2008.
View Article : Google Scholar
|
|
4
|
Hirota S, Isozaki K, Moriyama Y, et al:
Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heinrich MC, Corless CL, Duensing A, et
al: PDGFRA activating mutations in gastrointestinal stromal tumors.
Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stenman G, Eriksson A and Claesson-Welsh
L: Human PDGFA receptor gene maps to the same region on chromosome
4 as the KIT oncogene. Genes Chromosomes Cancer. 1:155–158. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lasota J and Miettinen M: Clinical
significance of oncogenic KIT and PDGFRA mutations in
gastrointestinal stromal tumours. Histopathology. 53:245–266. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal tumors. J Clin Oncol. 22:3813–3825.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corless C, Schroeder A, Griffith D, et al:
PDGFRA mutations in gastrointestinal stromal tumors: frequency,
spectrum and in vitro sensitivity to imatinib. J Clin Oncol.
23:5357–5364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cassier PA and Blay JY: Molecular response
prediction in gastrointestinal stromal tumors. Target Oncol.
5:29–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Blay JY: A decade of tyrosine kinase
inhibitor therapy: Historical and current perspectives on targeted
therapy for GIST. Cancer Treat Rev. 37:373–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Demetri GD, von Mehren M, Antonescu CR, et
al: NCCN Task force report: Update on the management of patients
with gastrointestinal stromal tumours. J Natl Compr Canc Netw.
8:S1–41. 2010.PubMed/NCBI
|
|
13
|
Mol CD, Dougan DR, Schneider TR, et al:
Structural basis for the autoinhibition and STI-571 inhibition of
c-Kit tyrosine kinase. J Biol Chem. 279:31655–31663. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Babb C, Schnugh D, Louw M, et al: Getting
the gist: what is the importance of molecular genetics in
gastro-intestinal stromal tumours (GIST). S Afr Gastroenterol Rev.
8:4–5. 2010.
|
|
15
|
Heinrich MC, Owzar K, Corless CL, et al:
Correlation of kinase genotype and clinical outcome in the North
American Intergroup Phase III Trial of imatinib mesylate for
treatment of advanced gastrointestinal stromal tumor: CALGB 150105
Study by Cancer and Leukemia Group B and Southwest Oncology Group.
J Clin Oncol. 26:5360–5367. 2008.
|
|
16
|
Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan
V, Lax I and Schlessinger J: Structural basis for activation of the
receptor tyrosine kinase KIT by stem cell factor. Cell.
130:323–334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abdulkareem FB, Rotimi O, Elesha SO and
Banjo AA: Immunophenotyping of gastrointestinal mesenchymal tumours
in Lagos, Nigeria. West Afr J Med. 28:358–362. 2009.PubMed/NCBI
|
|
18
|
Hartley RJ, Becker JHR, Van Der Walt H and
Luyhengo T: Gastro-intestinal stromal tumours (GISTs) - the
Pretoria experience and a literature review. S Afr J Surg.
49:128–131. 2011.PubMed/NCBI
|
|
19
|
Tran T, Davila JA and El-Serag HB: The
epidemiology of malignant gastrointestinal stromal tumors: an
analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol.
100:162–168. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tzen CY, Wang MN and Mau BL: Spectrum and
prognostication of KIT and PDGFRA mutation in gastrointestinal
stromal tumors. Eur J Surg Oncol. 34:563–568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agaram NP, Baren A, Arkun K, Dematteo NP,
Besmer P and Antonescu CR: Comparative ultrastructural analysis and
KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors.
Ultrastruct Pathol. 30:443–452. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miettinen M, Sobin LH and Lasota J:
Gastrointestinal stromal tumors of the stomach: a
clinicopathologic, immunohistochemical and molecular genetic study
of 1765 cases with long-term follow-up. Am J Surg Pathol. 29:52–68.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miettinen M, Makhlouf H, Sobin LH and
Lasota J: Gastrointestinal stromal tumors of the jejunum and ileum:
a clinicopathologic, immunohistochemical and molecular genetic
study of 906 cases before imatinib with long-term follow-up. Am J
Surg Pathol. 30:477–489. 2006. View Article : Google Scholar
|
|
24
|
Debiec-Rychter M, Dumez H, Judson I, et
al: Use of c-KIT/PDGFRA mutational analysis to predict the clinical
response to imatinib in patients with advanced gastrointestinal
stromal tumours entered on phase I and II studies of the EORTC Soft
Tissue and Bone Sarcoma Group. Eur J Cancer. 40:689. 2004.
View Article : Google Scholar
|
|
25
|
Debiec-Rychter M, Sciot R, Le Cesne A, et
al: KIT mutations and dose selection for imatinib in patients with
advanced gastrointestinal stromal tumours. Eur J Cancer.
42:1093–1103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Andersson J, Bumming P, Meis-Kindblom JM,
et al: Gastrointestinal stromal tumors with KIT exon 11 deletions
are associated with poor prognosis. Gastroenterology.
130:1573–1581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martín J, Poveda A, Llombart-Bosch A, et
al: Deletions affecting codons 557–558 of the c-KIT gene indicate a
poor prognosis in patients with completely resected
gastrointestinal stromal tumors: a study by the Spanish group for
Sarcoma Research (GEIS). J Clin Oncol. 23:6190–6198. 2005.
|
|
28
|
Yeh CN, Chen TW, Lee HL, et al: Kinase
mutations and imatinib mesylate response for 64 Taiwanese with
advanced GIST: preliminary experience from Chang Gung Memorial
Hospital. Ann Surg Oncol. 14:1123–1128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
He HY, Fang WG, Zhong HH, et al: Status
and clinical implication of c-KIT and PDGFRA mutations in 165 cases
of gastrointestinal stromal tumor (GIST). Zhonghua Bing Li Xue Za
Zhi. 35:262–266. 2006.(In Chinese).
|
|
30
|
Sakurai S, Fukasawa T, Chong JM, Tonaka A
and Fukayama M: C-kit gene abnormalities in gastrointestinal
stromal tumors (tumors of interstitial cells of Cajal). Jpn J
Cancer Res. 90:1321–1328. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sakurai S, Oguni O, Hironaka M, Fukayama
M, Morinaga S and Saito K: Mutations in c-kit gene exons 9 and 13
in gastrointestinal stromal tumors among Japanese. Jpn J Cancer
Res. 92:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirota S, Ohashi A, Nishida T, Isozaki K,
Kinoshita K, Shinomura Y and Kitamura O: Gain-of-function mutations
of platelet-derived growth factor receptor α gene in
gastrointestinal stromal tumors. Gastroenterology. 125:660–667.
2003.
|
|
33
|
Braggio DA, Braggio E, Small IA, et al:
The profile of platelet-derived growth factor receptor alpha
(PDGFRA) gene alterations in GIST patients (pts) from Brazil. J
Clin Oncol. 26:105612008.
|
|
34
|
Campbell MC and Tishkoff SA: African
genetic diversity: implications for human demographic history,
modern human origins and complex disease mapping. Annu Rev Genomics
Hum Genet. 9:303–333. 2008. View Article : Google Scholar
|
